Welcome to our dedicated page for GSK PLC news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK PLC stock.
GSK plc reports developments across its global biopharma business, including vaccines, respiratory medicines, infectious disease, immunology and oncology programs. Recurring updates include regulatory decisions and clinical evidence for products such as AREXVY, GSK's RSV vaccine, and Exdensur for severe asthma, along with data presentations, product indications and therapeutic-area access initiatives.
GSK news also covers manufacturing and supply agreements, commercial collaborations, public-health grant programs and product partnerships tied to its medicine and vaccine portfolio. As an American Depositary Share issuer, company updates may reflect both parent-company announcements and ADR-related market disclosures.
On July 14, 2020, GlaxoSmithKline (GSK) announced that the FDA Oncologic Drugs Advisory Committee voted 12-0 in favor of the benefit-risk profile of belantamab mafodotin, an investigational treatment for relapsed or refractory multiple myeloma. The committee recognized its potential for patients who have undergone at least four prior therapies. The recommendation stems from the DREAMM-2 clinical trial. While the FDA may consider this recommendation, it is not obliged to follow it. Belantamab mafodotin is not yet approved worldwide.